If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. Speaking of which, we noticed some great changes in Fairchem Organics' (NSE:FAIRCHEMOR) returns on capital, so let's have a look.
What Is Return On Capital Employed (ROCE)?
Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. To calculate this metric for Fairchem Organics, this is the formula:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
0.19 = ₹589m ÷ (₹3.8b - ₹650m) (Based on the trailing twelve months to September 2024).
Therefore, Fairchem Organics has an ROCE of 19%. In absolute terms, that's a satisfactory return, but compared to the Chemicals industry average of 13% it's much better.
See our latest analysis for Fairchem Organics
Historical performance is a great place to start when researching a stock so above you can see the gauge for Fairchem Organics' ROCE against it's prior returns. If you want to delve into the historical earnings , check out these free graphs detailing revenue and cash flow performance of Fairchem Organics.
What Can We Tell From Fairchem Organics' ROCE Trend?
We like the trends that we're seeing from Fairchem Organics. The data shows that returns on capital have increased substantially over the last four years to 19%. Basically the business is earning more per dollar of capital invested and in addition to that, 75% more capital is being employed now too. So we're very much inspired by what we're seeing at Fairchem Organics thanks to its ability to profitably reinvest capital.
Our Take On Fairchem Organics' ROCE
To sum it up, Fairchem Organics has proven it can reinvest in the business and generate higher returns on that capital employed, which is terrific. Astute investors may have an opportunity here because the stock has declined 39% in the last three years. With that in mind, we believe the promising trends warrant this stock for further investigation.
Since virtually every company faces some risks, it's worth knowing what they are, and we've spotted 3 warning signs for Fairchem Organics (of which 2 are a bit unpleasant!) that you should know about.
If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:FAIRCHEMOR
Fairchem Organics
Manufactures and sells specialty oleo chemicals and intermediate nutraceuticals.
Flawless balance sheet with slight risk.
Similar Companies
Market Insights
Weekly Picks

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

EU#4 - Turning Heritage into the World’s Strongest Luxury Empire

The "Easy Money" Is Gone: Why Alphabet Is Now a "Show Me" Story
Recently Updated Narratives

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08

Novo Nordisk - A Fundamental and Historical Valuation

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Popular Narratives

The "Sleeping Giant" Stumbles, Then Wakes Up
Undervalued Key Player in Magnets/Rare Earth

